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ABSTRACT  
Cholesterol-lowering response to 40mg simvastatin daily for 6 weeks was examined for 
associations with common genetic polymorphisms in key genes affecting simvastatin 
metabolism (CYP3A4 and CYP3A5) and transport (SLCO1B1).  In Whites (n = 608), 
SLCO1B1 521C was associated with lesser reductions of total and low-density lipoprotein 
cholesterol. Associations between SLCO1B1 521C and cholesterol response were not 
detected in African-Americans (n = 333). Associations between CYP3A4*22 or CYP3A5*3 
and cholesterol response were not detected in either race, and no significant race-gene or 
gene-gene interactions were detected. As several of the analyses may have been 
underpowered (especially the analyses in the African American cohort), the findings not 
suggesting an association should not be considered conclusive and warrant further 
investigation. The finding regarding SLCO1B1 521C in Whites was consistent with several 
previous reports. SLCO1B1 521C resulted in a diminished cholesterol-lowering response, 
but a marginal effect size limits utility for predicting simvastatin response. 
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INTRODUCTION 
Statins remain among the most prescribed classes of medication in the United States and 
are indicated for the prevention of cardiovascular disease [1]. By inhibiting HMG CoA (3-
hydroxy-3-methylglutaryl-coenzyme A) Reductase, statins decrease intrahepatic cholesterol 
synthesis, up-regulate hepatocyte surface low-density lipoprotein cholesterol (LDL-C) 
receptors, increase hepatic LDL-C uptake and ultimately decrease blood concentrations of 
LDL-C. Reduction in LDL-C concentration is common proxy measure of statin efficacy, with 
an estimated reduction in risk of major cardiovascular events of nearly 20% per mmol/L (38 
mg/dL) reduction in LDL-C [2]. However, not all patients respond favorably to statins. A 
substantial proportion of patients do not achieve cholesterol goals, and some experience 
adverse effects such as statin-induced myopathy (SIM) [3]. Clinical outcomes and 
cholesterol-lowering response to simvastatin have demonstrated associations with clinical 
factors including age, race, gender, smoking, diet, comorbidities and use of concomitant 
medications [4]. Genetic variation also appears to contribute to inter-individual variability in 
response to statins [5]. In recent decades, a plethora of candidate-gene studies and genome 
wide association studies (GWAS) have focused on genetic polymorphisms and patient 
response to statins. Polymorphisms in several genes (e.g., ABCB1, ABCG2, SLCO1B1, 
UGT1A1, UGT1A3, UGT2B7, CYP2C9, CYP2C19, CYP2C8, CYP2D6, CYP3A4 and 
CYP3A5) have been associated with statin blood concentrations, and polymorphisms in 
several additional genes (e.g., APOE, CETP, CLMN, CYP7A1, HMGCR, LDLR, LPA) have 
been associated with response to statins or incidences of SIM [6].  
 
For simvastatin, one of the most commonly prescribed statins [1], investigations have largely 
focused on SLCO1B1 - the gene encoding the organic anion transporting polypeptide 1B1 
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that mediates intrahepatic transport of simvastatin [7]. Increased simvastatin concentrations 
and an increased risk of myopathy have been associated with SLCO1B1 polymorphisms in 
several studies, prompting the Clinical Pharmacogenetics Implementation Consortium 
(CPIC) to establish formal prescribing recommendations for simvastatin based on SLCO1B1 
genotype-defined risk of SIM [7-10]. Although nearly 200 common variants in SLCO1B1 
have been described, SLCO1B1 521C (rs4149056) has the highest level of evidence. All of 
the haplotypes identified as having an increased risk of SIM (*5, *15, *17) in CPIC’s 
Recommended Dosing of Simvastatin Based on SLCO1B1 Phenotype contain the SLCO1B1 
521C polymorphism [10]. Myopathy risk is increased because the SLCO1B1 521C 
polymorphism results in increased systemic concentrations of simvastatin (secondary to 
decreased transport of simvastatin into hepatocytes), ultimately increasing the exposure of 
muscle to simvastatin [6, 7, 11]. Since the primary action of simvastatin occurs within 
hepatocytes, SLCO1B1 521C reduces also the cholesterol-lowering response to simvastatin. 
This association has been demonstrated in several clinical studies. Sortica et al. reported the 
percent reduction of LDL-C in a study of 216 Brazilian patients that received 20 mg 
simvastatin daily for 6 months was 38.6 ± 8.0, 39.9 ± 8.6, and 42.1 ± 15.8 for homozygous 
SLCO1B1 521C carriers, heterozygous SLCO1B1 521C carriers and wildtype, respectively 
[12]. Fu et al. reported the percent reduction of LDL-C in a study of 174 patients of Chinese 
ancestry that received 20 mg simvastatin daily for 4 months was 27.2 ± 5.4, 28.9 ± 5.9, and 
30.8 ± 5.4 for homozygous SLCO1B1 521C carriers, heterozygous SLCO1B1 521C carriers 
and wildtype, respectively [13]. As these reported findings were only suggestive trends, Dou 
et al. performed a meta-analysis of these studies and determined that the association 
between SLCO1B1 521C and cholesterol reductions was statistically significant [14]. 
Hopewell et al. reported similar findings in the Heart Protection Study of 18,705 patients that 
received 40 mg simvastatin daily for 4-6 weeks: the percent reduction of LDL-C was 42.4 ± 
0.2, 43.6 ± 0.4, and 44.7± 0.4 for homozygous SLCO1B1 521C carriers, heterozygous 
SLCO1B1 521C carriers and wildtype, respectively [15]. Although the relationship between 
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SLCO1B1 521C and cholesterol response has been reported in several independent 
studies, its marginal effect size substantially reduces its potential for clinical utility. 
 
As simvastatin is metabolized primarily by the cytochrome P450, family 3, subfamily A, 
polypeptides 4 and 5 enzymes (CYP3A4 and CYP3A5, respectively), associations have 
been reported between simvastatin pharmacokinetics/dynamics and functional 
polymorphisms in CYP3A4 and CYP3A5. Specifically, the decrease-of-function (DOF) 
CYP3A4*22 (rs35599367) and the loss-of-function (LOF) CYP3A5*3 (rs776746) 
polymorphisms have been associated with increased simvastatin concentrations [6, 16-18] 
and increased cholesterol-lowering response [19-22]. In fact, we reported significant 
associations between these polymorphisms and simvastatin concentrations in this cohort 
[17, 18]. Reports of associations between these polymorphisms and simvastatin response 
have also been published. Kivistö et al. reported that the mean percent reduction in total 
cholesterol was higher (31% vs. 17%, p = 0.026) in CYP3A5*3 homozygotes compared to 
CYP3A5*1/*3 or CYP3A5*1 homozygotes in a study of 69 Caucasians that received 
lovastatin, simvastatin, or atorvastatin (all primarily metabolized by CYP3A) [19]. However, 
the percent reduction in LDL-C was not statistically different in CYP3A5*3 homozygotes 
compared to CYP3A5*1/*3 or CYP3A5*1 homozygotes (31% vs. 46%, p = 0.083). No 
associations between CYP3A5*3 and LDL-C lowering were detected in the following reports: 
Fiegenbaum et al.’s analysis of 99 Europeans that received 20 mg simvastatin daily for 6 
months [23], Hu et al.’s analysis of 229 Chinese that received 40 mg simvastatin daily for 6 
weeks [21], Bailey et al.’s analysis of 291 Europeans of the Genetic Effects On STATins 
(GEOSTAT-1) that received 40 mg simvastatin daily for 3 months [24] and Hopewell et al.’s 
analysis of 18,705 Europeans of the Heart Protection Study (HPS) that received 40 mg 
simvastatin daily for 4-6 weeks [15]. These findings collectively do not suggest that 
CYP3A5*3 alters cholesterol-lowering response to simvastatin, at least not in the patient 
populations studied.  
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Studies of CYP3A4*22 and simvastatin response have been rare, and although associations 
have been reported, findings have been inconsistent. Elens et al. reported that the LDL-C 
reduction in CYP3A4*22 carriers was 7% greater compared to non-carriers (41% vs. 48%; p 
= 0.054) in 80 incident simvastatin users of the Rotterdam Study after adjusting for age, sex, 
baseline cholesterol and simvastatin dose and duration [20]. The mean daily dose of 
simvastatin required for optimal cholesterol control was nearly 40% less for CYP3A4*22 
carriers compared to non-carriers in a study of 84 hyperlipidemia patients (p = 0.042) [22]. 
Conversely, no association was reported between CYP3A4*22 and LDL-C lowering 
response in a study of 209 patients that received 10-40 mg simvastatin daily for 6 months 
[25].  It remains uncertain whether CYP3A4*22 affects simvastatin cholesterol lowering. 
 
Despite several reports of associations between increased simvastatin concentrations and 
the DOF CYP3A4*22 polymorphism or the LOF CYP3A5 polymorphism, associations 
between these polymorphisms and simvastatin cholesterol-lowering response have seldom 
been detected. The lack of genetic investigation of simvastatin response in African 
Americans and our recent reports of associations between these CYP3A polymorphisms and 
12-hour simvastatin concentrations in this cohort provided the rationale for this follow-up 
candidate gene study. Herein, we present our study aimed at evaluating the associations of 
CYP3A4*22, CYP3A5*3 and SLCO1B1 521C alleles with the cholesterol response to 40 mg 
simvastatin daily for 6 weeks in White and African-American participants of the Cholesterol 
and Pharmacogenetics (CAP) clinical trial.  
 
METHODS 
Study participants 
This candidate-gene analysis included 609 self-reported White and 335 self-reported 
African-American males and females aged ≥30 years that had a baseline total serum 
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cholesterol level between 160 and 400 mg/dL. The participants of CAP (ClinicalTrials.gov 
identifier NCT00451828) were recruited and enrolled at San Francisco General Hospital and 
the University of California, Los Angeles, School of Medicine, and collected baseline data 
included demographic, medical history, risk factors for coronary heart disease, physical 
examination, and clinical laboratory test results. They received 40 mg simvastatin daily for 6 
weeks, clinic visits occurred at 2-week intervals during the 6-week study and exclusion 
criteria included the following: concomitant use of medications (prescription or over-the-
counter) known to significantly alter patient cholesterol levels or simvastatin 
pharmacokinetics; known liver disease or elevated transaminase levels more than twice the 
upper limit of normal; uncontrolled hypertriglyceridemia, hypertension or diabetes mellitus; 
abnormal renal or thyroid function; current alcohol or drug abuse; and known statin 
intolerance. Compliance was determined by pill counts, and the CAP clinical trial was 
approved by institutional review boards at all clinical, laboratory and coordinating centers. 
Additional details of the clinical trial methodology were provided in the initial report of the 
CAP clinical trial [26].  
 
Genotype analyses 
SLCO1B1 T521C (rs4149056) was determined using the Cardio-MetaboChip (Illumina, San 
Diego, CA) genotyping platform, and CYP3A4*22 (rs35599367) was determined using a 
TaqMan® genotyping assay (C_59013445_10; Life Technologies, NY). CYP3A5*3 
(rs776746) was determined using the Illumina Human Hap 300 or Human Hap 610-Quad 
genotyping platform (Illumina, San Diego, CA) for Whites and was determined using a 
TaqMan® genotyping assay (C_26201809_30; Life Technologies) for African Americans. 
 
Ancestry and relatedness analysis 
To assess relatedness between participants, the Cardio-MetaboChip was used to calculate 
pairwise identity-by-state (IBS) distances [27]. To meet the assumption of independent 
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observations, tests were performed to determine whether any participants were first cousins 
or more closely related (pi_hat > 0.125). One member of a pair of African-American 
participants with pi_hat = 0.1653 was excluded, and two additional subjects were excluded 
due to high degrees of relatedness (final n = 941). To assess genetic ancestry of the 
participants, the resulting matrix of IBS distances was used to perform multidimensional 
scaling (MDS) analysis in Plink [28]. In addition to self-reported race, the first three MDS 
components were used as covariates in order to account for background genetic ancestry. 
 
Statistical analysis 
Baseline continuous variables were summarized by median and interquartile range and 
compared by race groups using the Wilcoxon rank sum test. Baseline categorical variables 
were summarized by counts and percentages and compared between race groups using the 
χ2 test (or Fisher’s exact where necessary). Monte Carlo estimates of the exact p-values for 
Hardy-Weinberg equilibrium within race groups were calculated using 10,000 permutations. 
Changes in cholesterol were determined by comparing measured concentrations of 
cholesterol in serum samples collected at baseline and at the 6-week post-treatment visit. 
Regression analyses were used to detect associations between genotypes (CYP3A4*22, 
CYP3A5*3 and SLCO1B1 T521C) and changes in LDL and total cholesterol.  Regression 
analyses were also used to test whether changes in LDL and total cholesterol were 
associated with 12-hour plasma concentrations of simvastatin. Based on previously reported 
findings regarding non-genetic influences on the cholesterol-lowering response to 
simvastatin in the CAP trial [26], we adjusted our models for covariates including race, 
smoking status, and age. Genetic ancestry (first 3 MDS components) was also included as a 
covariate. Differences in the cholesterol-lowering response by genotypes and race group 
were assessed in the race-combined cohort using a multiplicative interaction term 
(genotype*race). Race-specific differences in cholesterol-lowering response by genotypes 
were assessed in analyses stratified by race group. To assess whether the effects of 
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SLCO1B1 T521C on cholesterol-lowering response to simvastatin were dependent on 
CYP3A4 and/or CYP3A5 status, the following gene-gene interactions were tested by 
incorporating a multiplicative interaction term within unadjusted and adjusted regression 
models in both the race-combined and -stratified cohorts: SLCO1B1*CYP3A4, 
SLCO1B1*CYP3A5, SLCO1B1*CYP3A4/5 (CYP3A4 and CYP3A5 combined by the number 
of decreased function alleles), and SLCO1B1*CYP3A4/5 (CYP3A4 and CYP3A5 combined 
into extensive, intermediate, and poor metabolizers as previously described). Statistical 
analyses were performed using SAS version 9.3 (Cary, NC), and p < 0.05 was considered 
statistically significant. Adjustments for multiple comparisons were made using the Benjamini 
and Hochberg’s linear step-up method [29], limiting the false discovery rate to 5%. We 
estimated 80% power to detect a 14% difference in LDL-C reduction by CYP3A4*22 
genotype, a 5% difference by CYP3A5*3 genotype and an 8% difference by SLCO1B1 
T521C genotype in unadjusted models.  
 
RESULTS  
Baseline characteristics of the 941 CAP participants included in this analysis are presented 
in Table 1. Genotypes at all three loci were within Hardy-Weinberg equilibrium for both race 
groups, and minor allele frequencies of SLCO1B1 521C, CYP3A4*22 and CYP3A5*3 were 
consistent with those reported in other cohorts [21, 22, 29, 30]. Statistical analyses of the 
associations between cholesterol-lowering response to simvastatin and CYP3A4*22, 
CYP3A5*3 and SLCO1B1 521C genotypes are presented in Table 2.  
 
Results from the race-combined and -stratified analyses reveled that SLCO1B1 521C was 
the only genetic variable that was significantly associated with cholesterol-lowering response 
to simvastatin 40 mg daily for 6 weeks, and this relationship occurred only in Whites: 
reduction of LDL-C was 44±25, 55±19 and 57±22 mg/dL in Whites of C/C, T/C and T/T 
genotype, respectively (p = 0.038 without correction for multiple hypotheses), and reduction 
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of total cholesterol was 43±27, 57±21 and 60±24 mg/dL in Whites of C/C, T/C and T/T 
genotype, respectively (p = 0.008 without correction for multiple hypotheses). Although the 
race-combined analysis of SLCO1B1 521 C and LDL-C reduction resulted in a significant p-
value, data in the African-American cohort demonstrated a relationship (non-significant p-
value) with direction both opposing biological plausibility and opposite that in the White 
cohort and in the previously-reported analyses. Neither CYP3A4*22 nor CYP3A5*3 were 
associated with differences in cholesterol-lowering responses in either race or in the 
combined-race cohort. Race-gene and gene-gene interactions for each genotype (SLCO1B1 
521C, CYP3A4*22 and CYP3A5*3) were not statistically significant (interaction terms and p-
values not shown). Simvastatin cholesterol-lowering response was not associated with 12-
hour post-dose simvastatin concentrations in the race-combined and –stratified cohorts of 
CAP. 
 
 
 
DISCUSSION 
Our study findings regarding SLCO1B1 521C were consistent with those observed in HPS 
[15] and in the meta-analysis reported by Duo et al. [14]: SLCO1B1 521C was associated 
with a diminished cholesterol-lowering response. The consistencies regarding the magnitude 
and direction of this effect not only support the validity of our study but also provide addition 
evidence supporting the central role of SLCO1B1 in the pharmacology of simvastatin. 
Although readily observed in clinical studies, the effect is marginal and unlikely to provide 
prescribing guidance beyond its established role in CPIC’s recommendations regarding 
simvastatin myopathy [9, 10].  
 
Although associations between simvastatin pharmacokinetics and the functional 
polymorphisms CYP3A4*22 and CYP3A5*3 have been reported in several cohorts [6, 16-18] 
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including our recent reports of analyses conducted in this cohort [17, 18], reports of their 
association with the cholesterol-lowering response to simvastatin have been rare. In fact, 
associations have been detected in only a single cohort each (Kivistö et al. for CYP3A5*3 
and Elens et al. for CYP3A4*22) [19, 20]. Those cohorts were relatively small (n = 69 and n 
= 80 for the reports by Kivistö et al. and Elens et al., respectively), and the reported 
associations failed to replicated in subsequent analyses of other larger cohorts and in this 
analysis of CAP. Specifically, CYP3A4*22 was not associated with change in LDL-C in the 
report by Ragia et al. (n = 209) [25], and CYP3A5*3 was not associated with changes in 
LDL-C in the studies reported by Hu et al. (n = 229) [21], Fiegenbaum et al. (n = 99) [23], 
Bailey et al. (n = 291) and Hopewell et al. (n = 18,705) [15]. 
 
This study had several advantages. The cohort size was relatively large (n = 941) and 
included a significant number of African-Americans (n = 333), providing novel opportunity for 
genetic investigation in an understudied patient population. The availability of genotyping 
chip data was another advantage, allowing genetic-ancestry adjustment and the exclusion of 
related subjects. Another advantage was comprehensive data collection, allowing 
adjustments for several clinical variables (age, gender, smoking status). The eligibility criteria 
of the CAP clinical trial helped minimize confounding factors including comorbidities, diet and 
concomitant prescription and over-the-counter medications.  
 
Nevertheless, there were several limitations to this study: other genes reported to play a role 
(albeit a minor role compared with SLCO1B1 and CYP3A4/5) in simvastatin 
pharmacokinetics (e.g., ABCB1, ABCG2, UGT1A1, UGT1A3, UGT2B7, CYP2C9, CYP2C19, 
CYP2C8 and CYP2D6) or statin cholesterol-lowering response (e.g., APOE, CETP, CLMN, 
CYP7A1, HMGCR, LDLR, LPA) were not included [3-6]. Likewise, not all polymorphisms of 
CYP3A4, CYP3A5 and SLCO1B1 were included in this candidate-gene study, and epistatic 
and epigenetic factors were not investigated. Despite the associations between 12-hour 
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post-dose simvastatin concentrations and CYP3A4*22, CYP3A5*3 and SLCO1B1 521C in 
CAP that we reported previously, regression analyses did not reveal associations (results 
not shown) between cholesterol-lowering response and simvastatin concentration in the 
race-combined and –stratified cohorts of CAP. This was not entirely unexpected because the 
pharmacokinetic data was limited (i.e., significant discordance likely exists between 12-hour 
concentrations in plasma and daily systemic exposure in hepatocytes) [17,18]. Several of 
our analyses, especially the race-stratified analyses in the African American cohort, were 
underpowered. In fact, the analyses of SLCO1B1 521C in African Americans included only 
14 heterozygotes and did not include any 521C homozygotes. The lack of observable 
associations in this population should not be considered definitive, and further investigation 
is warranted.  
 
With proven efficacy and relatively few adverse effects, statins remain among the most 
commonly prescribed medication classes in the United States. Although most patients 
benefit, some are unable to attain cholesterol-reduction goals, some experience 
atherosclerotic events despite therapy, and some experience adverse events.  Despite the 
completion of hundreds of candidate gene studies and numerous GWAS, a clinically relevant 
pharmacogenetic test to predict statin efficacy has not yet emerged. Our finding regarding 
SLCO1B1 521C in Whites confirmed the findings from several other studies: SLCO1B1 
521C results in a diminished cholesterol-lowering response, but its marginal effect size limits 
utility for predicting simvastatin response. Although these common variants result in altered 
simvastatin metabolism (CYP3A4*22, CYP3A5*3) and transport (SLCO1B1 521C), their 
clinical utility for predicting inter-individual cholesterol-lowering response is not well 
supported. Future approaches utilizing multi-gene genetic-score approaches may prove 
superior for investigating the potential utility of these polymorphisms collectively to predict 
the cholesterol-lowering response or the efficacy (prevention of cardiovascular events) of 
simvastatin. 
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STUDY HIGHLIGHTS: 
 
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? 
Common functional variants in key genes involved in simvastatin metabolism (CYP3A4*22, 
CYP3A5*3) and transport (SLCO1B1 521C) have been associated with altered simvastatin 
concentrations in several studies. A marginal effect (diminished cholesterol reduction) of 
SLCO1B1 521C on simvastatin response has been reported in several studies, but results 
from studies of CYP3A4*22 or CYP3A5*3 and simvastatin response have had inconsistent 
results. 
 
WHAT QUESTION DID THIS STUDY ADDRESS? 
This candidate-gene analysis examined the association of common genetic polymorphisms 
affecting simvastatin metabolism (CYP3A4*22 and CYP3A5*3) and transport (SLCO1B1 
T521C) with the cholesterol-lowering effect of simvastatin in 333 African Americans and 608 
Whites that received 40 mg simvastatin daily for 6 weeks. 
 
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE? 
This analysis provided a unique opportunity to examine the relationships among simvastatin 
response and these polymorphisms (CYP3A4*22, CYP3A5*3 and SLCO1B1 T521C) in a 
sizeable African American population. Furthermore, we previously reported that these 
polymorphisms significantly affected simvastatin concentrations in this cohort, providing an 
opportunity to examine the influence of these polymorphisms on both the pharmacokinetics 
and pharmacodynamics of simvastatin. 
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HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL 
SCIENCE? 
Individually, common genetic polymorphisms affecting simvastatin metabolism (CYP3A4*22 
and CYP3A5*3) and transport (SLCO1B1 T521C) appear to have negligible/marginal 
influence on cholesterol response to simvastatin. Collectively, however, effect may be 
clinically relevant, and future studies involving genetic score approaches may be more 
successful.  
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Table 1. Baseline Characteristics 
 
Overall 
(n = 941) 
Whites 
(n = 608, 65%) 
African Americans 
(n = 333, 35%) p-value 
†Age, yr 53 ±  17 54 ±  16 52 ± 18 0.843 
†BMI, kg/m2 28 ±  7 27 ±  7 29 ±  7 <0.001 
†Compliance, % 98 ± 5 98 ±  5 98 ±  6 0.027 
‡Male gender 484 (51%) 322 (53%) 162 (49%) 0.206 
‡Smoker 187 (20%) 84 (14%) 103 (31%) <0.001 
CYP3A4*22  
allele frequency 
0.03 0.04 0.01 0.003 
CYP3A5*3 
allele frequency 
0.73 0.93 0.35 <0.001 
SLC01B1 521 C 
allele frequency 
0.10 0.14 0.02 <0.001 
 
BMI = body mass index. CYP3A4 = the gene encoding cytochrome P450, family 3, subfamily A, 
polypeptide 4. CYP3A5 = the gene encoding cytochrome P450, family 3, subfamily A, polypeptide 5. 
SLCO1B1 = the gene encoding solute carrier organic anion transporter family member 1B1. 
†Continuous variables are represented as median ± interquartile range and compared using the 
Wilcoxon rank sum test.  ‡Categorical variables are represented as count (%) and compared using the 
χ2 test or Fisher’s exact where necessary. Bolded p-values were significantly associated with LDL-C 
lowering response to simvastatin in the Cholesterol and Pharmacogenetics (CAP) clinical trial.  
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Table 2. Associations of CYP3A4*22, CYP3A5*3 and SLCO1B1 521C with changes in cholesterol levels after 40mg simvastatin daily for 6 
weeks 
 
Overall Whites African Americans 
 
n 
∆ LDL-C   
(mg/dL) 
∆ TC 
(mg/dL) n 
∆ LDL-C 
(mg/dL) 
∆ TC 
(mg/dL) N 
∆ LDL-C 
(mg/dL) 
∆ TC 
(mg/dL) 
CYP3A4          
*1/*1 864 -54 ± 22 -57 ± 24 561 -56 ± 21 -59 ± 23 303 -51 ± 24 -53 ± 25 
*1/*22 54 -56 ± 23 -60 ± 26 46 -58 ± 21 -62 ± 23 8 -44 ± 29 -50 ± 38 
†
p-value  0.816 0.444  0.489 0.307  0.376 0.742 
‡
p-value  0.898 0.726  0.901 0.783  0.820 0.963 
CYP3A5          
*1/*1 125 -49 ± 25 -51 ± 24 6 -56 ± 17 -57 ± 16 119 -48 ± 25 -51 ± 25 
*1/*3 216 -53 ± 22 -55 ± 24 73 -56 ± 20 -58 ± 22 143 -51 ± 24 -53 ± 25 
*3/*3 537 -57 ± 21 -59 ± 23 507 -57 ± 21 -59 ± 23 30 -53 ± 21 -57 ± 25 
†
p-value  0.464 0.328  0.507 0.414  0.832 0.683 
‡
p-value  0.726 0.669  0.901 0.828  0.972 0.963 
SLCO1B1          
C/C 14 -44 ± 25 -43 ± 27 14 -44 ± 25 -43 ± 27 0 - - 
C/T 151 -55 ± 19 -58 ± 21 137 -55 ± 19 -57 ± 21 14 -57 ± 20 -60 ± 23 
T/T 718 -55 ± 22 -58 ± 24 441 -57 ± 22 -60 ± 24 277 -51 ± 23 -54 ± 25 
†
p-value  0.103 0.028  0.038 0.008  0.310 0.305 
‡
p-value  0.495 0.204  0.366 0.107  0.783 0.783 
∆ LDL-C = change in low-density lipoprotein cholesterol. ∆ TC = change in total cholesterol. CYP3A4 = the gene encoding cytochrome P450, 
family 3, subfamily A, polypeptide 4. CYP3A5 = the gene encoding cytochrome P450, family 3, subfamily A, polypeptide 5. SLCO1B1 = the 
gene encoding solute carrier organic anion transporter family member 1B1. †Adjusted for age, smoking status, genetic ancestry (first 3 multi-
dimensional scaling components) and self-reported race (when applicable); ‡also corrected for multiple comparisons with a false discovery rate 
of 5%. Values are presented as mean ± standard deviation. Only p-values < 0.05 are bolded. 
 
